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Abstract 
As to the development of treatment for diabetes, Continuous Glucose Monitoring (CGM) has been recently prevalent rapidly. By the analysis of 
real-time CGM, Ambulatory Glucose Profile (AGP) has been used. It includes time in range (TIR, 70-180 mg/dL), time above range (TAR, 
>181mg/dL), time below range (TBR, <69 mg/dL), Glycemic Variability (GV), Glucose Management Indicator (GMI), Glycemic variability, 
Coefficient Of Variation (CV%) and so on. TIR value indicating approximately 70% seems to correlate closely with the HbA1c level of 6.7-
7.0%. Marked discordance of HbA1c values has been found between laboratory HbA1c and estimated HbA1c (eA1c) using GMI from CGM. 
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As to the development of treatment for diabetes, Continuous Glucose 
Monitoring (CGM) has been prevalent rapidly, including both of real-
time CGM (rtCGM) and intermittently scanned CGM (isCGM). Lots 
of studies demonstrated remarkable benefits of CGM for diabetes 
patients [1]. However, absence of clarified glycemic targets was 
observed from both patients and diabetes team cooperating together. 
Consequently, the Advanced Technologies and Treatments for 
Diabetes (ATTD) congress were convened for better management of 
practice and research. The objective included the development of 
clinical CGM-derived times in glucose ranges, such as above target 
range, within target range and below target range.  
 
 CGM continuously provides diabetic patients and medical staffs 
current glucose values and related data in order to make adequate 
treatment management [2]. Furthermore, real-time CGM systems can 
give attention for higher and lower glucose levels which allow 
necessary intervention for additional insulin or carbohydrate per os [3]. 
 
 In recent report, T1DM patients with rtCGM (n=70) were compared 
with control for impaired hypoglycemia awareness related to the 
HypoDE (Hypoglycemia in Deutschland) study. As a result, glucose 
threshold at taking rescue carbohydrate was increased from 71mg/dL to 
79mg/dL in the rtCGM group. It suggested earlier awareness for 
hypoglycemia with preventing hypoglycemia episodes [3].  
 
For T2DM cases with basal insulin without prandial insulin (n=175), 
glucose variability was compared for CGM group vs traditional blood 
glucose meter (BGM) group [1]. The comparative results for 8 months 
in both groups were as follows: HbA1c changes 9.1 to 8.0% vs 9.0 to 
8.4%, TIR (70-180mg/dL) 59% vs 43%, TAR (>250mg/dL) 11% vs  
 
27% and mean glucose levels 179mg/dL vs 206mg/dL. Consequently, 
CGM group showed more effective response.  
 
According to American Diabetes Association (ADA), diabetic patients 
with intensive insulin treatment are encouraged to check glucose 
changes by CGM [4]. Glucose profile was captured by CGM which 
was optimal method to clarify current glucose variability [5]. From the 
data of CGM, Time in Range (TIR) refers the time period of 70-180 
mg/dL during 24 hours. Furthermore, TIR is useful for estimating 
insulin response during short-term Continuous Subcutaneous Insulin 
Infusion (CSII) treatment. Recently, TIR value was reported to show 
both of micro vascular and macro vascular complications [6], 
neuropathy [7] and micro albuminuria [8].  
 
For CGM report, Ambulatory Glucose Profile (AGP) is used [9]. In 
some studies, lower Coefficient of Variation (CV%) targets would be 
adequate for 33% in the case who are treated by insulin or 
sulfonylureas [10]. Standardized CGM metrics for clinical care are as 
follows [5]: i) Number of days CGM worn (14-days recommended), ii) 
Percentage of time CGM (70% recommended), iii) Mean glucose, iv) 
Glucose Management Indicator (GMI), v) Glycemic variability (%CV 
<36%), vi) Time Above Range (TAR): >250mg/dL level 2, vii) TAR: 
181-250mg/dL, level 1, viii) TIR: 70-180 mg/dL, ix) Time Below 
Range (TBR): 54-69mg/dL level 1, x) TBR: <54mg/dL level 2.  
 
CGM-based targets for some patients are recommended. Target 
percentages of each factor are shown in the following: TIR >70%, 
TAR-L2 <5%, TAR-L1 <25%, TBR-L1 <4%, TBR-L2 <1% in type 1 
and type 2 diabetes, and TIR >50%, TAR-L2 <10%, TAR-L1 <50%, 
TBR-L1 <1%, in older/high-risk of type 1 and type 2 diabetes [5].  
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TIR and other metrics from CGM have become standardized factors 
from international consensus. TIR value of about 70% correlates 
closely with HbA1c level of 6.7-7.0% [11]. Several evidences are 
found on the relationship of TIR and diabetic complications, in which 
each 10% TIR elevation brings risk decrease for long-term 
complications. 
 
CGM data were collected for 5901 T2DM cases for 5 years, and 
analyzed for 3 profiles of Glycemic Variability (GV) [12]. They are i) 
TIR profile, ii) hypo profile, iii) hyper profile (N=2271, 1471, 2159, 
respectively). Comparative data between group i) vs iii) showed that 
fasting glucose 167 vs 203 mg/dL, 2-hr post prandial glucose 256 vs 
302 mg/dL, and HbA1c 8.6 vs 9.7%. Odds Ratio (OR) of ii) and iii) for 
i) showed that non-proliferative Diabetic Retinopathy (PDR) 1.44 and 
1.33, macro albuminuria 1.58 and 1.37, and diabetic kidney disease 
(DKD) 1.65 and 1.88 compared with i)TIR profile. Especially, ii) 
showed OR 2.84 for PDR.  
 
Recent report showed the relationship between TIR by CGM and body 
fat percentage in T2DM [13]. Subjects were 85 T2DM cases and they 
received CGM during short-term CSII therapy. As a result, T2DM 
cases with higher body fat exhibited lower TIR (p=0.004) and higher 
mean blood glucose levels (p=0.001). Thus, weight reduction can be 
therapeutic target to obtain better glucose variability for obese cases, 
which may get less beneficial effect from intensive insulin therapy.  
 
For CGM study for T1DM, TIR and CV% were analyzed for 95 cases 
[14]. Subjects number for HbA1c was 20 for ≤7%, 44 for 7-8%, 31 for 
>8%. TIR was negatively associated with HbA1C, mean blood glucose 
(MBG) and time spent in hyperglycemia (p<0.001), but not with time 
in hypoglycemia. The results suggested that TIR would be strongly 
related with hyperglycemia and CV% would be reflective of 
hypoglycemic risk.  
 
Lots of diabetic patients and related medical staffs have felt marked 
discordance of HbA1c values, between laboratory HbA1c and 
estimated HbA1c (eA1c) using GMI from CGM [15]. According to 
latest report, much data from 641 separate offices were analyzed. 
Subjects showed T1DM in 91% with mostly history of >20 years and 
24.5 days duration of CGM. As a result, 11% cases discordance <0.1%, 
50% vs 22% cases showed differences ≥0.5% vs ≥1%. Elevated 
discordance was found with advanced Chronic Kidney Disease (CKD), 
in which Estimated Glomerular Filtration Rate (eGFR) <60 mL/ 
min/1.73m2). Consequently, substantial discordance is present between 
laboratory HbA1c and eA1C in the actual clinical practice. 
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